



DR-TB DIRECTORATE

Update on BPaL-L rollout

Date: 07 October 2026



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Presentation outline



1. Introduction
2. Unpacking the regimens
3. Capturing challenges
4. Treatment outcomes
5. BDQ Resistance
6. Post success treatment follow-up patients management
7. Conclusion



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Introduction



Since its inception treatment initiation of BPAL-L has greatly improved from 17% to 86,4 % of all RR/MDR-TB patients initiated on treatment .

The next slide will show the trends of the RR/MDR-TB treatment initiation of the different regimens used in the RRTB management.

All eligible patients are initiated on the 6 months regimen

The trends will also show the phasing out of the 9 months regimen



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Unpacking the Regimens



	Individualized	Short Regimen (6 Months)	Short Regimen (9-11 Months)	Grand Total
2023 Q1	750	18	1243	2011
2023 Q2	701	52	1100	1853
2023 Q3	717	249	1030	1996
2023 Q4	433	973	506	1912
2023	2601 (33,5%)	1292 (16,6%)	3879 (49,9%)	7772
2024 Q1	311	1448	156	1915
2024 Q2	281	1245	125	1651
2024 Q3	224	1180	62	1466
2024 Q4	216	1236	61	1513
2024	1032 (15,8%)	5109 (78,1%)	404 (6,17%)	6545
2025 Q1	229	1272	38	1539
2025 Q2	206	1252	31	1489
2025 Q3	235	1334	33	1605
2025 Q4	194	1190	19	1404
2025	864 (14,3%)	5048 (83,6%)	121 (2,0%)	6037
2026 Q1	199	1260	13	1473
2026 Q2	155	1125	5	1286
2026	354 (12,8%)	2385 (86,4%)	18 (0,65%)	2759
Grand Total	4851	13834	4422	23113



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Challenges with capturing



Regimen Type	Type of Drug-Resistant TB	Current Treatment	All Treatment	Drug Resistance Pattern	Final Treatment Outcome	Months On Treatment
Short Regimen (9-11 Months)	Rifampicin Resistant	Bdq, Lfx, Lzd, Pa	Bdq, Lfx, Lzd, Pa	, R	Loss to Follow-Up	6
Short Regimen (9-11 Months)	Rifampicin Resistant			R	Not Specified	18
Short Regimen (9-11 Months)	Rifampicin Resistant		Bdq, Cfz, Lfx, Lzd, Pyridoxine, Trd	R	Died (D)	9
Short Regimen (9-11 Months)	Rifampicin Resistant		Bdq, Lfx, Pa	R	Treatment Completed (TC)	9
Short Regimen (9-11 Months)	MDR Not Confirmed	E, Lfx, R, Z	E, Lfx, R, Z		Treatment Completed (TC)	12
Short Regimen (9-11 Months)	MDR Confirmed		Bdq, Lfx, Lzd, Pa	, H, R	Cured (C)	8
Short Regimen (9-11 Months)	Rifampicin Resistant		Bdq, Cfz, Dlm, E, High dose INH, Lfx, Z	R	Died (D)	0
Short Regimen (9-11 Months)	MDR Not Confirmed		Cfz, Lfx, Lzd, PAS, Trd		Treatment Completed (TC)	7
Short Regimen (9-11 Months)	MDR Not Confirmed		Cfz, Lfx, Lzd, PAS, Trd		Treatment Completed (TC)	7
Short Regimen (9-11 Months)	MDR Not Confirmed		Bdq, Lfx, Lzd, Pa		Treatment Completed (TC)	9
Short Regimen (9-11 Months)	Rifampicin Resistant		B6, Bdq, Lfx, Lzd, Pa	R	Treatment Completed (TC)	9
Short Regimen (9-11 Months)	MDR Confirmed			, H, R	Moved Out	18
Short Regimen (9-11 Months)	MDR Confirmed		Bdq, Lfx, Lzd, Pa	H, R	Cured (C)	6
Short Regimen (9-11 Months)	MDR Confirmed		Bdq, Cfz, Lfx, Trd	, ETH, H, R	Treatment Completed (TC)	8



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Challenges with capturing



Regimen Type	Type of Drug-Resistant TB	Current Treatment	All Treatment	Drug Resistance Pattern	Final Treatment Outcome	Months On Treatment
Short Regimen (9-11 Months)	MDR Not Confirmed	Bdq, Dlm, Lfx, Lzd	Bdq, Dlm, Lfx, Lzd		Treatment Completed (TC)	10
Short Regimen (9-11 Months)	Pre-XDR	Bdq, Dlm, Lfx, Lzd, Pa, PAS, Trd	Bdq, Dlm, Lfx, Lzd, Pa, PAS, Trd	H, R, FQs	Not Specified	18
Short Regimen (9-11 Months)	Rifampicin Resistant	Bdq, Lfx, Lzd, Pa	Bdq, Lfx, Lzd, Pa	R	Loss to Follow-Up	11
Short Regimen (9-11 Months)	Pre-XDR		Bdq, Lfx, Lzd, Pa	ETH, H, R, FQs	Cured (C)	6
Short Regimen (9-11 Months)	Rifampicin Resistant		Bdq, Lfx, Lzd, Pa	, R	Treatment Completed (TC)	12
Short Regimen (9-11 Months)	Rifampicin Resistant	Bdq	Bdq	R	Not Specified	17
Short Regimen (9-11 Months)	MDR Confirmed		Bdq, Cfz, E, High dose INH, Lfx, Lzd, Z	H, R	Loss to Follow-Up	10
Short Regimen (9-11 Months)	MDR Confirmed		Bdq, Lfx, Lzd, Pa	H, R	Cured (C)	6
Short Regimen (9-11 Months)	MDR Confirmed		Bdq, Cfz, Lfx, Trd	, ETH, H, R	Treatment Completed (TC)	8



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Challenges with capturing



Regimen Type	Age At Treatment Start	Age Group	Gender	All Treatment	Final Treatment Outcome	Months On Treatment		
Individualized	11	05 TO UNDER 15	Female	Dlm, Eto, Lzd, Trd	Cured (C)		8	
Individualized	1	UNDER 5	Male	Bdq, Cfz, Lfx, Lzd, Trd	Cured (C)		8	
Individualized	2	UNDER 5	Male	Bdq, Cfz, Lfx, Lzd, Trd	Treatment Completed (TC)		9	
Individualized	1	UNDER 5	Female	Bdq, Cfz, Dlm, Lzd, MVT, Trd, Zinc	Treatment Completed (TC)		9	
Individualized	1	UNDER 5	Male	Bdq, Cfz, Lfx, Lzd, Trd	Treatment Completed (TC)		6	
Individualized	1	UNDER 5	Male	Bdq, Cfz, Lfx, Lzd, PYRIDOXINE, Trd	Treatment Completed (TC)		6	
Individualized	2	UNDER 5	Male	Bdq, Cfz, Lfx, Lzd, Trd	Treatment Completed (TC)		6	
Individualized	1	UNDER 5	Female	Bdq, Cfz, Lfx, Lzd, Trd	Cured (C)		6	
Individualized	2	UNDER 5	Male	Bdq, Cfz, Lfx, Lzd, Trd	Treatment Completed (TC)		9	
Individualized	2	UNDER 5	Female	Bdq, Cfz, Lfx, Lzd, Trd	Cured (C)		9	
Individualized	2	UNDER 5	Female	Bdq, Cfz, Lfx, Lzd, Trd	Treatment Completed (TC)		7	
Individualized	24	15 TO UNDER 25	Female	Bdq, Bedaquiline, Lfx, Lzd, Pa, Rifabutin	Treatment Failure (TF)		8	

Treatment outcomes, 6 month regimen January 2023-Dec 2025, RSA



	Success Rate	Death Rate	LTFU Rate	Not Specified	Transfer Out	NE Rate	TF Rate	Total
2023 Q1	72%	0%	22%	0	0	0%	6%	18
2023 Q2	77%	13%	9%	0	0	0%	0%	53
2023 Q3	74%	12%	10%	2	0	1%	3%	249
2023 Q4	78%	9%	10%	1	0	0%	2%	976
2023	77%	10%	10%	3	0	0%	2%	1296
2024 Q1	82%	8%	8%	3	1	0%	2%	1450
2024 Q2	80%	8%	9%	7	3	1%	2%	1246
2024 Q3	77%	8%	12%	5	4	1%	2%	1180
2024 Q4	77%	8%	11%	13	5	1%	2%	1249
2024	79%	8%	10%	28	13	1%	2%	5125
2025 Q1	77%	9%	11%	13	2	1%	2%	1282
2025 Q2	74%	9%	11%	41	3	4%	2%	1245
2025 Q3	72%	8%	12%	85	5	7%	2%	1326
2025 Q4	63%	8%	9%	204	15	19%	2%	1191
2025	72%	8%	11%	343	25	7%	2%	5044



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Treatment outcomes, 6-month regimen 2024 and 2025 cohorts, per Province



6-month regimen	Success Rate	Death Rate	LTFU Rate	Not Specified	Transfer Out	NE Rate	TF Rate	Grand Total
EASTERN CAPE								
2024	78%	11%	7%	7	3	1%	3%	1327
2025	71%	11%	11%	47	5	5%	2%	1036
FREE STATE								
2024	81%	6%	9%	0	2	1%	2%	162
2025	61%	10%	10%	32	3	17%	2%	211
GAUTENG								
2024	80%	7%	11%	0	0	0%	2%	566
2025	71%	8%	16%	1	1	0%	4%	514
KWAZULU-NATAL								
2024	84%	5%	7%	3	2	1%	2%	989
2025	79%	6%	6%	85	6	8%	2%	1171
LIMPOPO								
2024	82%	8%	6%	1	1	1%	3%	191
2025	79%	10%	3%	9	2	7%	1%	149
MPUMALANGA								
2024	80%	11%	6%	0	0	0%	3%	278
2025	77%	7%	7%	16	2	6%	3%	288
NORTH WEST								
2024	87%	9%	2%	0	0	0%	2%	195
2025	76%	12%	4%	18	1	9%	0%	221
NORTHERN CAPE								
2024	79%	8%	11%	0	1	0%	1%	209
2025	75%	13%	10%	4	0	2%	0%	228
WESTERN CAPE								
2024	73%	7%	17%	17	4	2%	2%	1208
2025	63%	6%	17%	131	5	12%	2%	1226

BDQ Resistance



The National Department of health introduced the BCAP between 2013 and 2014 for pre-XDR-TB cases.

The National scale-up was accelerated between 2015 and 2018 to replace the injectable drugs (Kanamycin etc.) standard regimens with safer, patient-friendly all oral drugs.

This transition significantly improved treatment success and reduced mortality as seen in the previous slide, though it now faces emerging resistance challenges.



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Comparison of BDQ_R patients from the total RR-TB diagnosed , January 2021-



NHLS Laboratory Confirmed pTB					EDRweb			
YEAR	RR-TB	BDQ-R	BDQ-R %	Difference	YEAR	RR-TB	BDQ-R	BDQ-R %
2021	9661	219	2.3%	149	2021	6892	70	1.0%
2022	10392	177	1.7%	90	2022	7844	87	1.1%
2023	9771	438	4.5%	235	2023	7774	203	2.6%
2024	8165	393	4.8%	154	2024	6546	239	3.7%
2025	7732	278	3.6%	61	2025	6026	217	3.6%
2026	3203	93	2.9%	23	2026	2521	70	2.8%



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



The number of BDQ_R patients, January 2021-June 2026



	2021	2022	2023	2024	2025	2026 (up to June)
	BDQ_R	BDQ_R	BDQ_R	BDQ_R	BDQ_R	BDQ_R
EASTERN CAPE	30	40	50	41	46	13
FREE STATE	1	0	5	6	4	2
GAUTENG	6	14	39	22	25	6
KWAZULU-NATAL	5	4	37	55	43	18
LIMPOPO	2	2	0	7	1	1
MPUMALANGA	3	1	5	4	6	1
NORTH WEST	0	2	5	5	2	0
NORTHERN CAPE	4	5	4	13	9	2
WESTERN CAPE	19	19	58	86	81	27
Grand Total	70	87	203	239	217	70



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Proportion of BDQ_R patients from the total RR-TB, January 2021-June 2026, RSA



	2021 BDQ_R/ RR-TB (%)	2022 BDQ_R/ RR-TB (%)	2023 BDQ_R/ RR-TB (%)	2024 BDQ_R/ RR-TB (%)	2025 BDQ_R/ RR-TB (%)	2026 (up to June) BDQ_R/ RR-TB (%)
EASTERN CAPE	30/1621 (1,9)	40/1884 (2)	50/1854 (3)	41/1603 (3)	46/1235 (4)	13/473 (3)
FREE STATE	1/252 (0,4)	0/299 (0)	5/255 (2)	6/198 (3)	4/242 (2)	2/93 (2)
GAUTENG	6/706 (0,8)	14/875 (1,6)	39/897 (4)	22/684 (3)	25/605 (4)	6/310 (2)
KWAZULU-NATAL	5/1703 (0,3)	4/1844 (0,2)	37/1765 (2)	55/1404 (4)	43/1427 (3)	18/669 (3)
LIMPOPO	2/207 (1,0)	2/239 (0,8)	0/262 (0)	7/214 (3)	1/154 (1)	1/95 (1)
MPUMALANGA	3/393 (0,8)	1/385 (0,3)	5/412 (1)	4/319 (1)	6/315 (2)	1/96 (1)
NORTH WEST	0/321 (0)	2/371 (0,5)	5/325 (2)	5/246 (2)	2/244 (1)	0/101 (0)
NORTHERN CAPE	4/295 (1,4)	5/350 (1,4)	4/303 (1)	13/240 (5)	9/261 (3)	2/126 (2)
WESTERN CAPE	19/1394 (1,4)	19/1597 (1,2)	58/1701 (3)	86/1638 (5)	81/1543 (5)	27/558 (5)
Grand Total	70/6892 (1,0)	87/7844 (1,1)	203/7774 (3)	239/6546 (4)	217/6026 (4)	70/2521 (3)



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



6 – month follow-up after being successfully treated, 2023 cohort



	Clinically Stable But Unable to Produce Sputum	Died	Loss to Follow-Up	Negative	Positive	No follow-up result	No result Rate	Grand Total
	45	7	27	916	13	4109	80,3%	5117
EASTERN CAPE	0	0	3	305	3	925	74,8%	1236
FREE STATE	0	0	0	46	2	119	71,3%	167
GAUTENG	10	3	8	125	2	445	75,0%	593
KWAZULU-NATAL	19	2	1	234	0	998	79,6%	1254
LIMPOPO	0	0	0	39	0	153	79,7%	192
MPUMALANGA	0	0	1	60	2	239	79,1%	302
NORTH WEST	0	0	0	28	1	211	87,9%	240
NORTHERN CAPE	0	0	0	23	0	183	88,8%	206
WESTERN CAPE	16	2	14	56	3	836	90,2%	927
Grand Total	45	7	27	916	13	4109	80,3%	5117



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



12 – month follow-up after being successfully treated, 2023 cohort



	Clinically Stable But Unable to Produce Sputum	Loss to Follow-Up	Negative	Positive	No Follow-up done	No Follow-up done rate	Grand Total
EASTERN CAPE	1		70		1165	94%	1236
FREE STATE			21	2	144	86%	167
GAUTENG	14	7	61	1	510	86%	593
KWAZULU-NATAL	20		91	1	1142	91%	1254
LIMPOPO			27		165	86%	192
MPUMALANGA			28	1	273	90%	302
NORTH WEST			8		232	97%	240
NORTHERN CAPE			9		197	96%	206
WESTERN CAPE	1	3	12		911	98%	927
Grand Total	36	10	327	5	4739	93%	5117



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



6 – month follow-up after being successfully treated, 2024 cohort



	Clinically Stable But Unable to Produce Sputum	Died	Loss to Follow-Up	Negative	Positive	No Follow-up done	No Follow-up done rate	Grand Total
EASTERN CAPE	1	3	0	216	6	961	81%	1187
FREE STATE	0	0	0	35	1	118	77%	154
GAUTENG	12	2	11	124	5	361	70%	515
KWAZULU-NATAL	22	3	0	199	4	856	79%	1084
LIMPOPO	0	2	0	24	0	144	85%	170
MPUMALANGA	0	1	0	43	6	195	80%	245
NORTH WEST	2	0	0	20	0	185	89%	207
NORTHERN CAPE	0	0	0	12	3	171	92%	186
WESTERN CAPE	58	0	7	46	0	964	89%	1078
Grand Total	95	14	18	719	25	3955	82%	4826



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



12 – month follow-up after being successfully treated, 2024 cohort



	Clinically Stable But Unable to Produce Sputum	Loss to Follow-Up	Negative	Positive	No Follow- up done	No Follow- up done rate	Grand Total
EASTERN CAPE	1	0	50	2	1134	96%	1187
FREE STATE	0	0	16	0	138	90%	154
GAUTENG	8	10	53	0	444	86%	515
KWAZULU-NATAL	18	0	75	0	991	91%	1084
LIMPOPO	0	1	5	1	163	96%	170
MPUMALANGA	0	0	18	0	227	93%	245
NORTH WEST	0	0	7	0	200	97%	207
NORTHERN CAPE	0	0	3	0	183	98%	186
WESTERN CAPE	15	2	16	1	1044	97%	1078
Grand Total	42	13	243	4	4524	94%	4826



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Conclusion



Total treatment numbers have fallen from 7,774 in 2023 to 6,037 in 2025, with further decline apparent in HY 2026.

Treatment has shifted decisively toward the 6-month regimen, which now accounts for 86,4% of reported treatments, while overall treatment volume continues to decline.

There are challenges with the capturing of patients that are extended to 9 months and those that are on the modified 6 months regimen

The relatively high number of BDQ_R is witnessed in the four provinces with the highest burden of DRTB in the country.



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Conclusion



The main concern is the LTFU, which at 10% is slightly higher than mortality at 8%. Together, death and LTFU account for 18% of outcomes.

The not-evaluated patients are mainly in the high DRTB provinces.

Patients should be provided with an outcome when it is due.

The high proportion of patients without documented follow-up results limits the ability to determine the proportion achieving sustained treatment success and to accurately estimate post-treatment TB recurrence.



health

Department:
Health
REPUBLIC OF SOUTH AFRICA





END
TB **BREATHE**
EASY



Thank You!